第二阶段持续时间对人类通过静脉除的强度持续时间关系的影响
1Department of Medicine, Division of Cardiology, University of Maryland School of Medicine, Baltimore, USA. sshorofs@medicine.umaryland.edu
Circulation
|November 1, 2000
概括
优化双相波形来实现除是关键. 将第二阶段缩短到2毫秒以下显著改善了人类的除门 (DFT),而更长的持续时间对DFT没有不利影响.
科学领域:
- 心血管医学 心血管医学
- 生物医学工程 生物医学工程
- 电子生理学 电子生理学
背景情况:
- 在除中双相波形有效性的精确机制仍然不完全理解.
- 针对除的最佳双相波形配置是正在进行的辩论的主题.
- 动物研究表明,将第二阶段延长到第一阶段之后,可能会提高除门 (DFT).
研究的目的:
- 在人类受试者中研究双相除波形第二阶段的强度-持续时间关系.
- 为了确定不同第二阶段持续时间对除功效的影响.
主要方法:
- 一项前性随机研究,涉及36名患者,使用双线圈透静系统.
- 每个患者评估了三个除门 (DFT),第二阶段的持续时间调整为1至18个月.
- 第一个阶段的持续时间固定在6毫秒,容量为150微法拉德.
主要成果:
- 只有当第二阶段脉冲持续时间减少到1毫秒时,在DFT时才观察到前沿电压的显著升高.
- 即使第二阶段的持续时间从2到18毫秒延长,DFT电压也保持不变.
- 储能,前沿电流和第二阶段能源的趋势相似,随着第二阶段持续时间的增加,正常化的第二阶段电流下降.
结论:
- 在人体中,双相除门 (DFT) 的电压和能量只有在第二阶段持续时间小于2 ms时才会改善.
- DFT电压表现出对第二阶段持续时间增加的不敏感性,长达18ms,是第一阶段持续时间的三倍.
相关概念视频
Time Course of Drug Effect
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...
Muscle Stimulation Frequency
The contraction strength of muscles is regulated by motor neurons, which modulate the frequency of action potentials dispatched to the motor units based on the body's requirements. This process of varying the muscle stimulation frequency allows muscles to contract with a force that is precisely tailored to the needs of the moment, whether lifting a feather or a heavy box.
Wave summation
At low firing rates, motor neurons induce individual twitch contractions in muscle fibers. These twitches...
Wave summation
At low firing rates, motor neurons induce individual twitch contractions in muscle fibers. These twitches...
Fatigue
Fatigue occurs when materials rupture under repeated or fluctuating loads, even at stress levels far below their static breaking strength. It typically results in brittle failure, even for ductile materials. It is a critical consideration in designing machines and structural components subjected to repetitive or varying loads. The nature of these loadings can range from fluctuating loads like unbalanced pump impellers causing vibrations to repeatedly bending a thin steel rod wire back and forth...
Fatigue Strength of Concrete
Fatigue, in the context of materials science and engineering, refers to the weakening or failure of a material caused by repeatedly applied loads, even if these loads are below the strength limit of the material. Fatigue strength in concrete is a critical property that influences its durability and longevity. Concrete can fail in two ways due to fatigue. Static fatigue or creep rupture occurs under a constant load or one that increases slowly. The other failure mode is due to cyclical or...
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.


